Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters.
BACKGROUND
Sarcoidosis is a multisystem disease of unknown origin characterized by the formation of noncaseating granulomas, in particular in the lungs, lymph nodes, eyes, and skin. Systemic treatment for cutaneous sarcoidosis can be used for large disfiguring lesions, generalized involvement, or recalcitrant lesions that did not respond to topical therapy.


METHODS
We report three patients with recalcitrant cutaneous sarcoidosis who were treated with oral fumaric acid esters (FAE). Three female patients presented with cutaneous sarcoidosis that have proved to be refractory to various therapies, including corticosteroids and chloroquine. We treated the patients with FAE in tablet form using two formulations differing in strength (Fumaderm initial, Fumaderm). Dosage of FAE was performed according to the standard therapy regimen for psoriasis patients. After treatment with FAE (4-12 months), a complete clearance of skin lesions was achieved in the three patients. The side effects observed in this trial correspond to the well-known spectrum of adverse effects of FAE (flush, minor gastrointestinal complaints, lymphopenia).


CONCLUSIONS
On the basis of our findings FAE therapy seems to be a safe and effective regimen for patients with recalcitrant cutaneous sarcoidosis. Nevertheless further investigations are necessary to confirm our preliminary results.
Nowack
Ute
U
Department of Dermatology, Ruhr-University Bochum, Bochum, Germany. UteNowack@web.de
Gambichler
Thilo
T
Hanefeld
Christoph
C
Kastner
Ulrike
U
Altmeyer
Peter
P
D000328:Adult; D000069462:Dimethyl Fumarate; D005260:Female; D005650:Fumarates / Q000008:administration & dosage*; D006801:Humans; D012507:Sarcoidosis / Q000188:drug therapy*; D012871:Skin Diseases / Q000188:drug therapy*
D005650:Fumarates; D000069462:Dimethyl Fumarate; C061175:ethyl fumarate